首页> 美国卫生研究院文献>Molecules >Design Synthesis Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
【2h】

Design Synthesis Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit

机译:具有磺酰脲单元的索拉非尼类似物的设计合成活性和对接研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Two series of novel sorafenib analogs containing a sulfonylurea unit were synthesized and their chemical structures were confirmed by 1H-NMR, 13C-NMR, MS spectrum and elemental analysis. The synthesized compounds were evaluated for the cytotoxicity against A549, Hela, MCF-7, and PC-3 cancer cell lines. Some of the compounds showed moderate cytotoxic activity, especially compounds 1-(2,4-difluorophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (>6c) and 1-(4-bromophenylsulfonyl)-3-(4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea (>6f) with the IC50 values against four cancer cell lines ranging from 16.54 ± 1.22 to 63.92 ± 1.81 μM, respectively. Inhibitory rates against vascular endothelial growth factor receptor-2 (VEGFR2/KDR) kinase at 10 μM of target compounds were further carried out in this paper in order to investigate the target of these compounds. Structure-activity relationships (SARs) and docking studies indicated that the sulfonylurea unit was important to these kinds of compounds. None of the substitutions in the phenoxy group and small halogen atoms such as 2,4-difluoro substitution of the aryl group contributed to the activity. The results suggested that sulfonylurea sorafenib analogs are worthy of further study.
机译:合成了两个含有磺酰脲单元的新型索拉非尼类似物,并通过 1 H-NMR, 1 3 C-NMR证实了其化学结构,质谱图和元素分析。评价合成的化合物对A549,Hela,MCF-7和PC-3癌细胞系的细胞毒性。一些化合物显示出中等的细胞毒活性,尤其是化合物1-(2,4-二氟苯基磺酰基)-3-(4-(2-(甲基氨基甲酰基)吡啶-4-基氧基)苯基)脲(> 6c )和1-(4-溴苯基磺酰基)-3-(4-(2-(甲基氨基甲酰基)吡啶-4-基氧基)苯基)脲(> 6f ),对四种癌细胞系的IC50值从16.54±1.22到63.92±1.81μM。为了研究这些化合物的靶标,在本文中进一步针对10μM的目标化合物执行了对血管内皮生长因子受体2(VEGFR2 / KDR)激酶的抑制率。结构活性关系(SARs)和对接研究表明,磺酰脲单元对这些化合物很重要。苯氧基和小的卤原子如芳基的2,4-二氟取代均无贡献。结果表明磺酰脲索拉非尼类似物值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号